Despite decisions by firms like Atlas Venture and Mohr Davidow to exit the early stage diagnostic space, other VCs believe the evolution of underlying technologies and the long-term need to control healthcare costs make it an ideal time to invest.

In a pair of blog posts last month, Atlas' Bruce Booth painted a pessimistic picture of the outlook for venture investing in diagnostics.